Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors-Reference-Cited by-同舟云学术

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors

Published:2016-03 Issue:3 Volume:29 Page:255-269
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Goel Shom,Wang Qi,Watt April C.,Tolaney Sara M.,Dillon Deborah A.,Li Wei,Ramm Susanne,Palmer Adam C.,Yuzugullu Haluk,Varadan Vinay,Tuck David,Harris Lyndsay N.,Wong Kwok-Kin,Liu X. Shirley,Sicinski Piotr,Winer Eric P.,Krop Ian E.,Zhao Jean J.

Funder

NIH

Susan G. Komen

Breast Cancer Research Foundation

Aid for Cancer Research

Institutional Research Grant of Hollings Cancer Center

Medical University of South Carolina

National Health and Medical Research Council of Australia

Genentech

AstraZeneca

Acetylon

Gilead Pharmaceuticals

Novartis

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference29 articles.

1. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics;Arteaga;Cancer Cell,2014

2. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer;Berns;Cancer Cell,2007

3. The toxicity of poisons applied jointly;Bliss;Ann. Appl. Biol.,1939

4. Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa);Carey;J. Clin. Oncol.,2014

5. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity;Chandarlapaty;Cancer Cell,2011

Cited by 355 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for breast cancer: New strategies to enhance the patient selection and overcome therapeutic resistance;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Dose reduction and discontinuation due to the combination of CDK4/6 inhibitors and endocrine drugs: a systematic review and meta-analysis;European Journal of Clinical Pharmacology;2024-09-13

3. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment;Drug Resistance Updates;2024-09

4. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14

5. mTORC1 activity oscillates throughout the cell cycle, promoting mitotic entry and differentially influencing autophagy induction;Cell Reports;2024-08